Clinical Trial Update: Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer [Phase 1, Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update reports results from a Phase 1/2 study evaluating the combination of margetuximab and pembrolizumab in advanced, metastatic HER2-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• MARGENZA (MARGETUXIMAB-CMKB)

Snippet

Sponsor: MacroGenics | Conditions: Gastric Cancer, Stomach Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-04